Previous Article | Next Article ![]()
Journal of Virology, December 2006, p. 11520-11527, Vol. 80, No. 23
0022-538X/06/$08.00+0 doi:10.1128/JVI.00287-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Department of Microbiology, Oregon State University, 220 Nash Hall, Corvallis, Oregon 97331-3804
Received 8 February 2006/ Accepted 7 September 2006
|
|
|---|
|
|
|---|
The origin of the virion membranes is not well understood. At the present time, there are two hypotheses explaining formation of the primary (crescent) membrane surrounding IV and IMV particles. One of them suggests that the membrane is synthesized de novo, induced by virus infection (3). Other studies have proposed that the primary membrane is derived from the intermediate endoplasmic reticulum (ER)-Golgi compartment (ERGIC). It has been shown that the membranes contiguous with crescents are labeled with intermediate ERGIC markers (33) and that IMV envelope proteins A17L, A14L, and A13L accumulate at the ERGIC during virus infection (14, 29). So far, all attempts to confirm this model and detect host cell proteins from ERGIC or any other cellular compartment incorporated into IMV particles have been unsuccessful (13). It is also not clear what intracellular membranes are used to generate the secondary membrane that wraps IEV. Schmelz and coworkers (31) suggested that IEV is surrounded by modified TGN membranes. Others provided evidence suggesting a hypothesis that the secondary membrane originates from endosomal cisternae (35, 37). Supporting these models, both TGN and endosomal markers ß-1,4-galactosyltransferase and transferrin receptor CD71, respectively, were shown to be associated with purified EEV particles (13).
In the work reported here, we demonstrate that a TGN membrane protein, golgin-97, not only copurifies with VV particles but is also found to be a virion component. In VV-infected cells, golgin-97 is shown to translocate to the viral factories. In the purified virions the protein is detected in a proteolytically processed form. Immunoelectron microscopy, proteinase protection assays, and virion fractionation results suggest that golgin-97 is associated with insoluble virus core proteins, but consistent with its rod-like structure the protein seems to penetrate the virion envelope and protrude through the virion surface.
|
|
|---|
Clones and plasmids. golgin-97 (GOLGA1) cDNA clone (ID IOH27115) was purchased from Invitrogen (Ultimate ORF Clones collection). In order to insert FLAG sequence upstream or downstream of the golgin-97 open reading frame, its cDNA sequence was amplified by PCR with the following sets of primers: N-terminal FLAG-golgin-97 fusion, 5'-CACCATGGATTATAAAGACGATGACGACAAGTTTGCAAAACTGA-3' and 5'-CTAGGACCATGGTATCC-3'; C-terminal FLAG-golgin-97 fusion, 5'-CACCATGTTTGCAAAACTGA-3' and 5'-CTACTTGTCGTCATCGTCTTTATAATCGGACCATGGTATCC-3'. The PCR product was subcloned into the pcDNA6.2/V5/GW/D-TOPO vector (Invitrogen), yielding pN-FLAG:G97 and pC-FLAG:G97 constructs expressing N-terminal and C-terminal FLAG-golgin-97 fusion proteins, respectively.
Antibodies. Anti-human golgin-97 (GOLGA1) mouse monoclonal antibodies and CDF4 and CDFX clones were purchased from Invitrogen and GeneTex, Inc. (San Antonio, TX), respectively. Anti-FLAG mouse monoclonal antibodies were purchased from Sigma-Aldrich, Inc. (St. Louis, MO). Rabbit polyclonal anti-I3L antibodies (40) were kindly provided by J. Krijnse-Locker (European Molecular Biology Laboratory, Heidelberg, Germany). Rabbit polyclonal anti-L1R and anti-p25 antibodies were produced by our lab and have been described elsewhere (15, 25).
Transfections and infections. HeLa cells were grown in six-well plates to 80% confluency and transfected with 1µg of plasmid DNA using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. At 24 h posttransfection, the cells were infected with VV WR at a multiplicity of infection (MOI) of 5.0 PFU per cell. After 24 h of incubation the cells were harvested and analyzed by immunoblot assay. For virus purification, the cells were grown in eight 100-mm plates and transfected with 3 µg of plasmid DNA using the same protocol. At 3 h posttransfection the cells were infected with VV WR at an MOI of 5.0 PFU/cell and incubated for 40 h. Virus purification was carried out according to the protocol described above.
Immunofluorescence staining for confocal laser scanning microscopy. The cells were plated on glass coverslips in 24-well plates at 30% to 40% confluency. The next day, the cells were infected with vaccinia virus strain WR at an MOI of 1.0 PFU/cell. At the indicated times postinfection, HeLa and McCoy cells were fixed with 100% methanol for 10 min. 293 and BSC-40 cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS, pH 7.4) for 20 min and then permeabilized in 0.2% Triton X-100 in PBS for 10 min. The coverslips were washed three times with PBS, blocked in 2% bovine serum albumin (BSA)-PBS (pH 7.4) (P-BSA) for 30 min, and incubated with primary rabbit anti-I3L (1:2,000) and mouse anti-golgin-97 (1 µg/ml) CDF4 antibodies diluted in P-BSA for 1 h. The cells were washed three times with PBS and once with P-BSA and then incubated with anti-rabbit (Southern Biotechnology Associates, Inc., Birmingham, AL) and anti-mouse (Invitrogen) antibodies conjugated to tetramethylrhodamine isothiocyanate (TRITC) and Alexa Fluor 488, respectively. The coverslips were mounted in ProLong Gold antifade reagent with 4',6-diamidino-2-phenylindole (DAPI; Invitrogen) and analyzed with a Zeiss LSM 510 Meta confocal laser scanning microscope. The channels were collected in multitrack mode.
Electron microscopy. (i) Immunogold labeling of thin sections. HeLa and 293 cells were infected with VV WR at an MOI of 5 PFU/cell. At 24 h postinfection (hpi), the cells were scraped from the plates, resuspended in culture medium, and pelleted by centrifugation at 700 x g, 4°C. The cells were fixed in 1% paraformaldehyde, 0.5% glutaraldehyde, 200 mM cacodylate buffer (pH 7.4) for 4 h. Embedding in LR White resin and sectioning were performed by personnel of the Oregon State University Electron Microscopy laboratory. The thin sections were placed on uncoated gold 300-mesh grids. The grids were blocked in P-BSA for 1 h at room temperature and incubated with primary mouse anti-golgin-97 CDF4 antibodies (4 µg/ml) in P-BSA for 1 h at room temperature and then overnight at 4°C. The sections were washed in six droplets of PBS and one droplet of P-BSA (5 min/each) and then incubated with secondary anti-mouse antibodies conjugated to 18-nm gold (Jackson Immunoresearch Laboratories, Inc., West Grove, PA) diluted 1:20 in P-BSA for 3 h at room temperature. The grids were washed in six droplets of PBS (5 min/each) and deionized water and stained with lead citrate and uranyl acetate. The samples were examined on a Philips EM 300 electron microscope.
(ii) Immunogold labeling of purified VV WR virions. Approximately 108 particles were applied to carbon-coated gold 300-mesh grids and air dried. The samples were processed as described previously (1) with minor modifications. The virions were fixed in 4% paraformaldehyde in PBS for 1 h and permeabilized with 0.2% Triton X-100 in PBS or left unpermeabilized. The grids were washed three times in PBS, blocked in 5% BSA, 2% normal goat serum in PBS (pH 7.4) for 30 min, and incubated with primary golgin-97 antibodies CDF4 (4 µg/ml) diluted in blocking solution as described above. For virion permeabilization experiments, the grids were washed and incubated with secondary 5-nm gold-conjugated anti-mouse antibodies (Sigma-Aldrich, Inc.) diluted 1:20 in blocking solution. Alternatively, the virions were labeled with anti-golgin-97 CDF4 antibodies and anti-mouse antibodies conjugated to 30-nm gold particles (Ted Pella, Inc., Redding, CA) using the same protocol. The samples were stained with ammonium molybdate and examined on a Philips EM 300 electron microscope.
Immunoblot analysis. HeLa, BSC-40, and McCoy cells were mock infected or infected with the indicated viruses at an MOI of 10 PFU/cell and incubated for 17 hpi. The infected cells were harvested, pelleted by centrifugation at 700 x g, 4°C, and resuspended in 10 mM Tris (pH 8.0). The cells were lysed by freeze-thawing and cleared by centrifugation at 1,500 x g, 4°C. The samples were equalized based on the measured optical density at 280 nm. VV and CPX virions were purified as described above. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride membrane (Immobilon-PSQ; Millipore, Billerica, MA). The membrane was blocked in 3% gelatin in TTBS (0.05% Tween 20, 150 mM NaCl, 50 mM Tris-HCl, pH 7.4) and incubated with primary rabbit anti-L1R (1:4,000), rabbit anti-p25 (1:2,000), or mouse anti-golgin-97 CFD4 (1 µg/ml) and CDFX (1:100) antibodies in 1% gelatin-TTBS overnight. The membrane was washed three times in TTBS and incubated with secondary anti-rabbit (Promega, Madison, WI) or anti-mouse (Invitrogen) antibodies conjugated to horseradish peroxidase. The proteins were detected with a chemiluminescence kit (West-Pico; Pierce Biotechnology, Inc., Rockford, IL).
Fractionation of purified VV WR virions. The virions were fractionated by detergent treatment according to a previously published protocol (1) with some modifications. Briefly, the virions (1010 particles) were incubated in 1% NP-40, 50 mM dithiothreitol (DTT), 5 mM MgCl2, Tris-HCl (pH 8.0) buffer for 30 min at room temperature. Membrane and core proteins were separated by centrifugation at 14,000 x g, 4°C. The cores were divided into soluble and insoluble fractions by incubation with 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate for 30 min at room temperature, followed by centrifugation at 14,000 x g, 4°C. The fractions were analyzed by immunoblotting.
Proteinase protection assay. Purified virions (4 x 108 particles) were incubated in 1 mM CaCl2, 50 mM Tris-HCl (pH 8.0) buffer in either the presence or absence of trypsin (50 µg/ml; Promega) for 1 h at room temperature. The digestion reaction was stopped by the addition of SDS-PAGE sample buffer. The samples were analyzed by immunoblotting.
|
|
|---|
hruby/supp.htm). Viral DNA replication factories appear to organize initially in close proximity to golgin-97 accumulation sites, the TGN membranes (Fig. 1B). The golgin-97 translocation to the viral factories was detected at 6 hpi (Fig. 1C). By 24 hpi, most of golgin-97 accumulated in the factories as discrete punctate bodies (Fig. 1F). Although an overlap in golgin-97 and I3L accumulation sites could be noticed in some cells, the proteins seemed to distribute to distinct subdomains within the virosome. Similar relocation of golgin-97 into the virosome was also detected in another human cell line, 293 cells infected with VV WR (data not shown). All of the 126 examined VV-infected HeLa cells contained virosomes with golgin-97 inclusions, although the size and number of inclusions varied for each individual cell.
![]() View larger version (41K): [in a new window] |
FIG. 1. Localization of golgin-97 protein in infected cells by confocal laser scanning microscopy. HeLa cells were mock infected (A) or infected with VV WR at an MOI of 1.0 PFU/cell (B, C, D, E, and F). The infected cells were fixed at 3, 6, 9, 12, and 24 hpi and stained with primary anti-golgin-97 and anti-I3L antibodies and secondary antibodies conjugated to Alexa Fluor 488 (green channel) and TRITC (red channel), respectively. Host and viral DNA were stained with DAPI (blue channel). All panels show merged images. Aqua, yellow, and magenta areas demonstrate an overlay of green and blue, green and red, and blue and red channels, respectively. Bars, 5 µm. Viral factories are highlighted with dashed lines. Note: I3L, previously shown to be expressed early in infection and localize to viral factories (28, 40), was used as a marker for the infected cells and viral factories.
|
97 kDa) in both the BSC-40 and McCoy cell lines (data described below). The immunofluorescence assay showed that by 24 hpi, BSC-40 and McCoy golgin-97 orthologs also assembled in punctate structures inside viral factories analogous to those found in human cell lines (data not shown). This suggested that similar mechanisms of golgin-97 redistribution exist in all other host species infected with VV WR, implying that this phenomenon is induced by virus infection. golgin-97 accumulates in close proximity to VV virions in infected cells. To study golgin-97 accumulation at viral DNA replication sites in more detail, ultrathin sections of VV-infected cells were examined by immunoelectron microscopy. The infected cells were fixed at 24 hpi and processed for immunolabeling with primary anti-golgin-97 antibodies and secondary antibodies conjugated to 18-nm gold particles. In agreement with the earlier study, gold particles indicating golgin-97 accumulation were found in the virosomal area. Heavy labeling was detected around electron-dense structures that appeared to be the previously described DNA crystalloids (Fig. 2A) and inclusion bodies (Fig. 2 A, B, and C) (8, 34). Moreover, some of the gold grains were observed in close proximity to IV and IMV particles and seemed to be associated with both of the virion forms (Fig. 2B and C), leading to a hypothesis that golgin-97 might be a virion component.
![]() View larger version (61K): [in a new window] |
FIG. 2. Subcellular localization of golgin-97 in VV WR-infected cells by immunoelectron microscopy. Infected cells were fixed at 24 hpi. Ultrathin sections were stained with primary anti-golgin-97 antibodies and secondary antibodies conjugated to 18-nm gold particles. golgin-97 distribution was similar to that demonstrated in immunofluorescence experiments. It accumulated in the virosomal area around electron-dense structures previously described as DNA crystalloids (A) and inclusion bodies (A, B, and C) (8, 34). Some gold grains were detected in close proximity to IVs (B) and IMVs (C) (indicated by arrows). Bars, 500 nm. DC, DNA crystalloids; IB, inclusion bodies.
|
60 kDa). To confirm that the 60-kDa band is a golgin-97 fragment, we tested VV virions with the other antibodies against golgin-97, clone CDFX. These antibodies also recognized a 60-kDa protein fragment in the purified virus, suggesting that golgin-97 is processed in the infected cell either before or after its incorporation into the virus particle. To exclude the possibility that the protein band resulted from immunological cross-reaction between golgin-97 antibodies and abundant virus core proteins p4a and p4b, we tested the antibodies by immunofluorescence and immunoblot assays (data not shown). Both assays revealed no immunological cross-reactivity between the core proteins and golgin-97 antibodies and vice versa.
![]() View larger version (43K): [in a new window] |
FIG. 3. Immunoblot analysis of purified poxvirus virions with anti-golgin-97 monoclonal antibody clone CDF4 (A) and clone CDFX (B). VV WR virions were propagated and purified from cell lines of three different species, human (HeLa), monkey (BSC-40), and mouse (McCoy). VV COP, VV IHD-J, and CPX virus preparations were isolated from BSC-40 cells. UN, uninfected cell lysate; IN, infected cell lysate. Both monoclonal antibodies specific to human golgin-97 were reported previously to cross-react with golgin-97 orthologs from other vertebrate species. The masses of protein standards (in kDa) are shown on the left.
|
60 kDa) (Fig. 3), implying that digestion of golgin-97 and its incorporation into the virion could be common for other orthopoxviruses as well. C-terminal FLAG-golgin-97 fusion protein incorporates into poxvirus virions. Because the antibodies used in the experiment described above are monoclonal, the other products of proteolytic cleavage of golgin-97 remained undetected by immunoblot analysis. In order to identify other fragments of the protein potentially incorporated into poxvirus virions and to confirm golgin-97 targeting to the virions, we have propagated and purified VV from cells transiently expressing a FLAG-golgin-97 fusion protein.
The FLAG sequence was inserted either upstream or downstream of the golgin-97 open reading frame and subcloned under control of the cytomegalovirus promoter. The resulting plasmids expressing N-terminal and C-terminal FLAG-golgin-97 fusion proteins were named pN-FLAG:G97 and pC-FLAG:G97, respectively.
Transient expression of the fusion proteins in uninfected HeLa cells demonstrated that the protein fusions are expressed at the full length (
97 kDa) and detected by both anti-golgin-97 and anti-FLAG antibodies (Fig. 4A and B). In the infected cell lysates expressing either N-terminal or C-terminal fusion protein, anti-golgin-97 antibodies detected an additional band of approximately 80 kDa (Fig. 4A), thus confirming that the protein is processed in the presence of virus. The failure to detect those bands in untransfected cells is likely due to insufficient amounts of the processed endogenous golgin-97 protein. Also, we cannot exclude that golgin-97 overexpression or presence of the FLAG sequence may result in a different proteolytic digestion pattern. Immunoblot analysis with anti-FLAG antibodies of the infected cell lysates expressing the C-terminal FLAG-golgin-97 fusion showed two other protein bands (
70 kDa and
25 kDa) that were not recognized by golgin-97 CDF4 antibodies (Fig. 4B). Similarly, these protein bands were not detected by another golgin-97 antibody, clone CDFX (data not shown). Because the 70-kDa band does not contain anti-golgin-97 antibody epitopes, it is likely that the previously found golgin-97 60-kDa fragment is produced by an alternative processing of the protein.
![]() View larger version (40K): [in a new window] |
FIG. 4. Immunoblot analysis of purified VV WR virions propagated in the presence of transiently expressed N-terminal or C-terminal FLAG-golgin-97 fusion proteins. The samples were tested with golgin-97 CDF4 antibodies (A) and anti-FLAG antibodies (B). The left and middle panels show uninfected and VV WR-infected lysates of untransfected (UNT) cells or cells transfected with either pN-FLAG:G97 (N) or pC-FLAG:G97 (C). VV, VVn, and VVc refer to VV WR virions purified from untransfected cells and cells transfected with pN-FLAG:G-97 or pC-FLAG:G-97, respectively. Protein bands specific to the C-terminal FLAG-golgin-97 fusion protein (B) are labeled with asterisks. The masses of protein standards (in kDa) are shown on the left.
|
70 kDa) is incorporated into the virions (Fig. 4B). These results confirm targeting of golgin-97 fragments into poxvirions and strongly suggest that the previously detected 60-kDa protein band is in fact a golgin-97 fragment. None of the N-terminal FLAG-golgin-97 fusion protein fragments was detected in the purified virions, indicating that the FLAG sequence may be cleaved prior to or interfere with incorporation of the protein into virions. Hence, it is possible that there are additional golgin-97 fragments incorporated in the virion which have yet to be identified. Subviral localization of golgin-97. To determine the subviral localization of golgin-97, we fixed purified VV virions. The samples were labeled with anti-golgin-97 CDF4 antibodies and 5-nm gold-conjugated secondary antibodies either before or after permeabilization with Triton X-100 and examined by immunoelectron microscopy. Both permeabilized (Fig. 5B) and nonpermeabilized (Fig. 5A) virions were labeled in a similar manner. The gold grains remained outside the virion, suggesting that the protein is exposed at the virion surface and is likely to be incorporated in the virion envelope. This interpretation would be also consistent with the fact that golgin-97 is a membrane protein.
![]() View larger version (107K): [in a new window] |
FIG. 5. Immunoelectron microscopy analysis of purified VV WR virions. Virus particles were applied to a carbon-coated gold 300-mesh grid, air dried, and fixed. Unpermeabilized virions (A) or virions permeabilized with Triton X-100 (B) were labeled with primary anti-golgin-97 CDF4 and secondary antibodies conjugated to 5-nm gold. (C) Virions decorated with golgin-97 CDF4 and 30-nm gold-conjugated secondary antibodies. The size of each bar is shown above it.
|
![]() View larger version (36K): [in a new window] |
FIG. 6. Fractionation and proteinase protection assay of purified VV WR virions. (A) Virion envelope proteins (M) were solubilized in the presence of 1% NP-40 and 50 mM DTT and isolated from cores by centrifugation. The pelleted cores were separated into soluble (C1) and insoluble (C2) fractions by treatment with 0.1% SDS and 0.5% sodium deoxycholate following centrifugation. VV refers to purified VV WR particles prior to detergent treatment. (B) Purified virions were incubated in the presence or absence of trypsin. The samples were analyzed by immunoblotting and probed with antibodies to golgin-97 and viral proteins L1R and p25, previously found in membrane and core fractions, respectively.
|
Purified virions were also examined with golgin-97 CDFX antibodies by immunogold electron microscopy and a proteinase protection assay. The results were similar to those obtained with CDF4 antibodies (data not shown), suggesting that the epitopes for both golgin-97 antibodies are exposed at the virion surface and are likely located in the same protein region close to each other. With both permeabilized and nonpermeabilized virions, we observed some variation in the number of associated gold grains. The proteinase protection assay demonstrated high sensitivity of the protein to proteinases, suggesting that a fraction of the exposed golgin-97 epitopes could be degraded during the virus purification process. Hence, it is possible that some of the incorporated protein would remain undetectable by the monoclonal antibodies used in our experiments.
|
|
|---|
60 kDa) and likely to be a product of virus-induced proteolytic processing of golgin-97. Transient expression of N-terminal and C-terminal FLAG-golgin-97 fusion proteins in the infected cells revealed other potential products of the protein proteolytic digestion. In addition to this, one of those fragments,
70-kDa C-terminal FLAG:golgin-97, was found inside the virions propagated and purified from the cells transiently expressing the fusion protein, thus confirming that golgin-97 becomes processed and incorporated into poxvirus particles during virus infection. The results of virion fractionation and immunogold electron microscopy showed that the golgin-97 60-kDa fragment fractionates with insoluble core proteins and at the same time is exposed at the virion surface. The golgin-97 protein (97 kDa), an autoantigen associated with Sjogren's syndrome, was cloned by screening a HeLa cDNA library with serum from Sjogren's syndrome patients (7). golgin-97 belongs to the group of GRIP domain proteins. It has a rod-like structure with extensive coiled-coil regions and a conserved GRIP domain at its extreme C terminus (2, 12, 23). The presence of the GRIP domain was shown to be necessary and sufficient for protein targeting to the cytoplasmic surface of the TGN membrane (2, 12, 23). Immunoprecipitation experiments, cross-linking, and yeast two-hybrid analyses suggest that all GRIP domain proteins, including golgin-97, form parallel coiled-coil homodimers (20). Recruitment of golgin-97 to the TGN membrane is facilitated by the Arl1 protein, a member of the ARF/Arl family of small GTPases via its interactions with the GRIP domain (17-19, 32). The functions of golgin-97 in the cell are still unclear. Due to shared similarities in structure and localization with other golgins, the protein was proposed to play the role of a tethering molecule in vesicle trafficking and/or to be a TGN matrix protein (6). Recent studies have implicated golgin-97 in regulation of both endocytic and exocytic vesicular trafficking (16, 19).
Our results on golgin-97 subviral localization are fully supported by the presence of large coiled-coil regions in the protein sequence, implying that it can adopt a long rod-like structure. Taking into consideration the ability of the protein to form dimers, we propose that golgin-97 in monomeric form or as a homodimer becomes incorporated into the virion via its interactions with one or several core proteins comprising the insoluble fraction. The protein extends through the virion envelope and becomes exposed at the surface of the virion (Fig. 7). Although golgin-97 does not possess a transmembrane domain, its transmembrane localization inside the virion could be explained either by its potential lipid modification, possibly induced by virus, or by its interactions with viral membrane proteins. Immunoblotting analysis of transiently expressed golgin-97 and its truncated versions tagged with FLAG (data not shown) suggests that the epitopes for the monoclonal antibodies used in our experiments lie close to the N terminus of the protein. Therefore, it is likely that the golgin-97 N-terminal region stays outside the virion. It has yet to be determined whether golgin-97 proteolysis occurs before its incorporation into the virion or after, but we cannot exclude the possibility that there are additional golgin-97 fragments trapped inside the virion.
![]() View larger version (143K): [in a new window] |
FIG. 7. Working model. Based on the predicted rod-like structure of golgin-97 and its ability to form dimers, we propose that golgin-97 becomes incorporated into the virion either in the form of monomer or as a homodimer via its interactions with one or several core proteins comprising the insoluble fraction. The processed protein extends through the virion envelope and becomes exposed at the surface of the virion.
|
We acknowledge the Confocal Microscopy Facility of the Center for Gene Research and Biotechnology and the Environmental and Health Sciences Center at Oregon State University. We thank Jacomine Krijnse-Locker (EMBL, Heidelberg, Germany) for providing anti-I3L-antibodies, Michael Nesson (Electron Microscopy Laboratory, Oregon State University) for assistance with electron microscopy, and Cliff Gagnier for help with virus purification.
Published ahead of print on 20 September 2006. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»